Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis

NCT05199337 is registered in ClinicalTrials.gov with K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05199337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05199337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
Lead sponsor
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2021
Completion date
February 14, 2024
Enrollment
18 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

al amyloidosis, amyloidosis